Clinical Trials
120 trialsAMYLOCARP
Ramsay Générale de Santé
CArdiag
Lantheus Biosciences Ltd.
Towards Effective, Patient-tailored Anti-plasma Cell Therapies in AL Amyloidosis: Predicting Drug Response and Overcoming Drug Resistance
Fondazione IRCCS Policlinico San Matteo di Pavia
Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis
Fondazione IRCCS Policlinico San Matteo di Pavia
MED-hATTR
The Cleveland Clinic
BMT
Massachusetts General Hospital
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
SWOG Cancer Research Network
EMN27
European Myeloma Network B.V.
A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
Alexion Pharmaceuticals, Inc.
Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
Alexion Pharmaceuticals, Inc.
Repeat PET/CT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid Load
University of Tennessee Graduate School of Medicine
Screening to Improve Survival in AL Amyloidosis
Tufts Medical Center
Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
DOrianT
Takeda
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
Barbara Ann Karmanos Cancer Institute
COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies
Barbara Ann Karmanos Cancer Institute
High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis
Eastern Cooperative Oncology Group
Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis
The Cleveland Clinic
Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis
Icahn School of Medicine at Mount Sinai
A Study on the Management and Outcome of Patients With Systemic AL Amyloidosis in Europe
European Myeloma Network B.V.
AT03-001
Attralus, Inc.
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
University of Iowa
124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis
University of Tennessee Graduate School of Medicine
Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
National Cancer Institute (NCI)
CAST
The Cleveland Clinic
ALF
The Cleveland Clinic
MRD
Boston Medical Center
Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
Northwestern University
DUAL
Medical College of Wisconsin
Daratumumab for the Treatment of Patients With AL Amyloidosis
Boston Medical Center
Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)
University of Athens
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
Roswell Park Cancer Institute
CATALYST
University College, London
BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients
Peking Union Medical College Hospital
Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
Boston Medical Center
A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
Boston Medical Center
Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis
Boston Medical Center
Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis
Tufts Medical Center
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
Jonsson Comprehensive Cancer Center
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
Jonsson Comprehensive Cancer Center
Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial
Case Comprehensive Cancer Center
Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis
Memorial Sloan Kettering Cancer Center
Treatment for Chronic Pain in Patients With Advanced Cancer
Canadian Cancer Trials Group
Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis
Takeda
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
Columbia University
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
Fred Hutchinson Cancer Center
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies
Fred Hutchinson Cancer Center
Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden
M.D. Anderson Cancer Center
Quality of Life (QOL) Registry for Patients With AL Amyloidosis
Prothena Biosciences Ltd.
PRONTO
Prothena Biosciences Ltd.